Active, not recruitingPhase 3NCT03375320
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Studying Functioning neuroendocrine tumor of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Jennifer A ChanAlliance for Clinical Trials in Oncology
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 298 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2026
Study locations (30)
- Katmai Oncology Group, Anchorage, Alaska, United States
- Kingman Regional Medical Center, Kingman, Arizona, United States
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States
- PCR Oncology, Arroyo Grande, California, United States
- Sutter Auburn Faith Hospital, Auburn, California, United States
- Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
- Mills-Peninsula Medical Center, Burlingame, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Epic Care-Dublin, Dublin, California, United States
- Epic Care Partners in Cancer Care, Emeryville, California, United States
- Kaiser Permanente-Fremont, Fremont, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03375320 on ClinicalTrials.govOther trials for Functioning neuroendocrine tumor of pancreas
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT04919226Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSEITM Solucin GmbH
- RECRUITINGNCT00830557Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic DisordersMayo Clinic
See all trials for Functioning neuroendocrine tumor of pancreas →